MDM2 and cancer: Given that not all families with the R337H mutation present with other cancers, the authors tested for the presence of other genetic variants within TP53 (R72P and ins16) and MDM2 (SNP309) that have been reported to affect tumor susceptibility and age at onset in R337H mutation carriers, respectively [11-14].